Is AbbVie (ABBV) Fairly Valued As Skyrizi And Lung Cancer Updates Lift Optimism?

AbbVie (ABBV) is back in focus after filing with the European Medicines Agency for a subcutaneous induction regimen of Skyrizi in moderately to severely active Crohn's disease, alongside fresh lung cancer data from the 2026 World Conference on Lung Cancer.

These Skyrizi and lung cancer updates arrive as AbbVie trades at US$259.99, with the stock posting a 19.74% 90 day share price return and a 26.49% 1 year total shareholder return. This suggests that momentum has picked up again after recent short term volatility.

Spot fresh momentum stories like AbbVie by scanning our hand picked 19 high quality undiscovered gems that pair strong fundamentals with underappreciated pipelines.

For AbbVie, that sharp move sits between two clear explanations. Is the market finally catching up with the company’s expanding pipeline, or has sentiment simply swung too far ahead of reasonable value?

Most Popular Narrative: 4.9% Undervalued

AbbVie’s most followed narrative pegs fair value at about $273 per share versus the last close at $259.99, which frames the recent momentum as only partially pricing in its longer term story.

Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.

Read the complete narrative.

Curious what justifies paying up for AbbVie on 2029 earnings power. This narrative leans on faster profit growth, higher long run margins, and a premium multiple story that is anything but conservative.

Result: Fair Value of $273 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, even this optimistic AbbVie narrative can be knocked off course if new competitors pressure key therapies or if drug pricing reforms prove more restrictive than expected.

Find out about the key risks to this AbbVie narrative.

Another View on AbbVie: Rich P/E Versus Supportive Cash Flows

There is a clear clash between valuation methods for AbbVie. On one side, the Simply Wall St DCF model suggests the stock at $259.99 trades well below an estimated future cash flow value of $458.79, which points to an undervalued setup based on long term cash generation.

On the other side, AbbVie screens as expensive on earnings today, with a 73.3x P/E compared with a fair ratio of 42.9x, a US Biotechs industry average of 16.8x and a peer average of 29x. That gap implies meaningful valuation risk if sentiment cools before earnings catch up. Which lens do you trust more when the two tell such different stories?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern around AbbVie feels familiar, do not leave it there. Take a closer look at the balance of 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond AbbVie?

Do not stop with AbbVie. Broaden your watchlist now so you are not chasing the next move after it happens.

Target dependable compounders by reviewing our 12 dividend fortresses that can help anchor your portfolio with income while you assess growth stories like AbbVie.

Hunt for mispriced potential using the 50 high quality undervalued stocks to spot companies where fundamentals and price appear out of sync.

Reduce portfolio stress by scanning the 74 resilient stocks with low risk scores and focus your attention on businesses that score well on resilience and balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com